Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including Ascites
Hand-out
Press Releases
Martin Pharmaceuticals  
December 3, 2024

Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including Ascites

NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Martin Pharmaceuticals, a clinical-stage pharmaceutical company developing CIQUAAX® (docarpamine) for the treatment of complications arising from advanced liver disease, today announced that it

avatar profile Olean Times Herald

Olean Times Herald


Local & Social